Ardelyx (NASDAQ:ARDX) Shares Gap Up – Should You Buy?

Shares of Ardelyx, Inc. (NASDAQ:ARDX) gapped up before the market opened on Wednesday. The stock had previously closed at $3.03, but opened at $3.41. Ardelyx shares last traded at $3.1950, with a volume of 904,939 shares changing hands.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: TD Cowen initiated coverage with a “Strong Buy” rating; it also recently reaffirmed a Buy rating. HC Wainwright maintained its Buy rating and $13 price target. Read more: TD Cowen coverage
• Positive Sentiment: Ardelyx completed enrollment in the Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, a development milestone ahead of future trial results. Read more: ACCEL trial enrollment
• Neutral Sentiment: Q3 EPS of $0.00 beat the consensus forecast for a $0.02 loss, while revenue of $127.66 million was slightly below estimates of $127.99 million. Revenue grew 21% year over year. Read more: Q3 results
• Negative Sentiment: Multiple law firms publicized a pending securities class action, with a November 16 lead-plaintiff deadline. The lawsuit alleges Ardelyx misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these are allegations, not established findings. The legal overhang may weigh on sentiment. Read more: Class action notice
• Negative Sentiment: HC Wainwright raised its Q4 2026 and FY2026 EPS estimates, but sharply cut forecasts for FY2027 ($0.06 from $0.35) and FY2029 ($1.18 from $1.56), with smaller reductions for FY2028 and FY2030. Those longer-range cuts temper the near-term estimate improvements.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ARDX shares. Piper Sandler reduced their price target on shares of Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price on shares of Ardelyx in a research note on Tuesday, August 18th. Citigroup lowered their price target on Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a report on Monday, August 10th. TD Cowen began coverage on shares of Ardelyx in a research report on Wednesday. They set a “strong-buy” rating for the company. Finally, Zacks Research upgraded shares of Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $13.90.

Ardelyx Stock Performance

The company has a debt-to-equity ratio of 1.54, a quick ratio of 3.15 and a current ratio of 3.45. The company has a market capitalization of $737.77 million, a price-to-earnings ratio of -13.43 and a beta of 0.79. The firm has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $5.26.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 35.30% and a negative net margin of 11.85%. The firm’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.08) EPS. On average, sell-side analysts anticipate that Ardelyx, Inc. will post -0.20 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider James Brady sold 15,136 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $58,424.96. Following the completion of the transaction, the insider directly owned 245,930 shares of the company’s stock, valued at $949,289.80. The trade was a 5.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Foster sold 8,562 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $33,049.32. Following the sale, the insider owned 409,410 shares in the company, valued at approximately $1,580,322.60. This trade represents a 2.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 126,059 shares of company stock valued at $486,588. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

Several hedge funds and other institutional investors have recently made changes to their positions in ARDX. CenterBook Partners LP boosted its position in shares of Ardelyx by 29.0% during the 3rd quarter. CenterBook Partners LP now owns 60,140 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 13,536 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Ardelyx during the 3rd quarter worth about $39,000. Chicago Partners Investment Group LLC raised its position in shares of Ardelyx by 33.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 57,655 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 14,563 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ardelyx during the third quarter worth approximately $44,000. Finally, Profund Advisors LLC lifted its stake in Ardelyx by 6.1% during the third quarter. Profund Advisors LLC now owns 111,771 shares of the biopharmaceutical company’s stock worth $382,000 after purchasing an additional 6,433 shares during the last quarter. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.